No Data
No Data
Express News | Exact Sciences Shares Are Trading Higher After the Company Shared New Modeling Data on the Projected Impact of Its Cologuard Test Since Its FDA Approval
Glenview Capital's Q2 Moves Include Selling Broadcom After Just One Quarter, Exiting Meta
Express News | Exact Sciences Shared New Modeling Data Describing The Projected Impact Of The Cologuard Test On Patients, Health Care Professionals, And The U.S. Health Care System Since Its FDA Approval 10 Years Ago
New Modeling Data Show the Cologuard Test Has Detected More Than 623,000 Cancers and Precancers Over Past Decade, Saving U.S. Health Care System $22 Billion
Why You Should Add Exact Sciences (EXAS) to Your Portfolio
9 Health Care Stocks Whale Activity In Today's Session
No Data